226 related articles for article (PubMed ID: 32527945)
1. Urinary Lithogenic Risk Profile in ADPKD Patients Treated with Tolvaptan.
Bargagli M; Dhayat NA; Anderegg M; Semmo M; Huynh-Do U; Vogt B; Ferraro PM; Fuster DG
Clin J Am Soc Nephrol; 2020 Jul; 15(7):1007-1014. PubMed ID: 32527945
[TBL] [Abstract][Full Text] [Related]
2. Sodium and urea excretion as determinants of urine output in autosomal dominant polycystic kidney disease patients on V2 receptor antagonists: impact of dietary intervention.
Côté G; Asselin-Thompstone L; Mac-Way F; René de Cotret P; Lacroix C; Desmeules S; Agharazii M
Int Urol Nephrol; 2020 Feb; 52(2):343-349. PubMed ID: 32008201
[TBL] [Abstract][Full Text] [Related]
3. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
Boertien WE; Meijer E; de Jong PE; ter Horst GJ; Renken RJ; van der Jagt EJ; Kappert P; Ouyang J; Engels GE; van Oeveren W; Struck J; Czerwiec FS; Oberdhan D; Krasa HB; Gansevoort RT
Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953
[TBL] [Abstract][Full Text] [Related]
4. Short-Term Tolvaptan Increases Water Intake and Effectively Decreases Urinary Calcium Oxalate, Calcium Phosphate and Uric Acid Supersaturations.
Cheungpasitporn W; Erickson SB; Rule AD; Enders F; Lieske JC
J Urol; 2016 May; 195(5):1476-1481. PubMed ID: 26598423
[TBL] [Abstract][Full Text] [Related]
5. Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.
Torres VE; Higashihara E; Devuyst O; Chapman AB; Gansevoort RT; Grantham JJ; Perrone RD; Ouyang J; Blais JD; Czerwiec FS;
Clin J Am Soc Nephrol; 2016 May; 11(5):803-811. PubMed ID: 26912543
[TBL] [Abstract][Full Text] [Related]
6. Determinants of Urine Volume in ADPKD Patients Using the Vasopressin V2 Receptor Antagonist Tolvaptan.
Kramers BJ; van Gastel MDA; Boertien WE; Meijer E; Gansevoort RT
Am J Kidney Dis; 2019 Mar; 73(3):354-362. PubMed ID: 30578153
[TBL] [Abstract][Full Text] [Related]
7. Prostaglandin E2, Osmoregulation, and Disease Progression in Autosomal Dominant Polycystic Kidney Disease.
Geurts F; Xue L; Kramers BJ; Zietse R; Gansevoort RT; Fenton RA; Meijer E; Salih M; Hoorn EJ;
Clin J Am Soc Nephrol; 2023 Nov; 18(11):1426-1434. PubMed ID: 37574650
[TBL] [Abstract][Full Text] [Related]
8. Tolvaptan treatment is associated with altered mineral metabolism parameters and increased bone mineral density in ADPKD patients.
Bargagli M; Vetsch A; Anderegg MA; Dhayat NA; Huynh-Do U; Faller N; Vogt B; Ferraro PM; Fuster DG
Nephrol Dial Transplant; 2023 Jun; 38(7):1645-1654. PubMed ID: 36309473
[TBL] [Abstract][Full Text] [Related]
9. The role of urinary supersaturations for lithogenic salts in the progression of autosomal dominant polycystic kidney disease.
Ferraro PM; Bargagli M; Faller N; Anderegg MA; Huynh-Do U; Vogt B; Gambaro G; Fuster DG
J Nephrol; 2023 May; 36(4):1011-1018. PubMed ID: 36528688
[TBL] [Abstract][Full Text] [Related]
10. Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease.
Horie S; Muto S; Kawano H; Okada T; Shibasaki Y; Nakajima K; Ibuki T
Clin Exp Nephrol; 2021 May; 25(5):467-478. PubMed ID: 33471240
[TBL] [Abstract][Full Text] [Related]
11. Potential effect of tolvaptan on polycystic liver disease for patients with ADPKD meeting the Japanese criteria of tolvaptan use.
Mizuno H; Sekine A; Suwabe T; Ikuma D; Yamanouchi M; Hasegawa E; Sawa N; Ubara Y; Hoshino J
PLoS One; 2022; 17(2):e0264065. PubMed ID: 35176098
[TBL] [Abstract][Full Text] [Related]
12. Urinary EGF Receptor Ligand Excretion in Patients with Autosomal Dominant Polycystic Kidney Disease and Response to Tolvaptan.
Harskamp LR; Gansevoort RT; Boertien WE; van Oeveren W; Engels GE; van Goor H; Meijer E
Clin J Am Soc Nephrol; 2015 Oct; 10(10):1749-56. PubMed ID: 26231191
[TBL] [Abstract][Full Text] [Related]
13. Tolvaptan in Japanese patients with later-stage autosomal dominant polycystic kidney disease.
Oguro M; Kogure Y; Hoshino J; Ubara Y; Mizuno H; Sekine A; Kawada M; Sumida K; Hiramatsu R; Hasegawa E; Yamanouchi M; Hayami N; Suwabe T; Sawa N; Takaichi K
J Nephrol; 2018 Dec; 31(6):961-966. PubMed ID: 30357715
[TBL] [Abstract][Full Text] [Related]
14. Association of plasma somatostatin with disease severity and progression in patients with autosomal dominant polycystic kidney disease.
Messchendorp AL; Spithoven EM; Casteleijn NF; Dam WA; van den Born J; Tonnis WF; Gaillard CAJM; Meijer E;
BMC Nephrol; 2018 Dec; 19(1):368. PubMed ID: 30567514
[TBL] [Abstract][Full Text] [Related]
15. Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease.
Grantham JJ; Chapman AB; Blais J; Czerwiec FS; Devuyst O; Gansevoort RT; Higashihara E; Krasa H; Zhou W; Ouyang J; Perrone RD; Torres VE;
Nephrol Dial Transplant; 2017 Jun; 32(6):969-975. PubMed ID: 27190355
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease.
Edwards ME; Chebib FT; Irazabal MV; Ofstie TG; Bungum LA; Metzger AJ; Senum SR; Hogan MC; El-Zoghby ZM; Kline TL; Harris PC; Czerwiec FS; Torres VE
Clin J Am Soc Nephrol; 2018 Aug; 13(8):1153-1161. PubMed ID: 30026287
[TBL] [Abstract][Full Text] [Related]
17. Identifying the main predictors of urine output in autosomal-dominant polycystic kidney disease (ADPKD) patients taking tolvaptan.
Utiel FJB; García AIM; Moyano AP; Oporto FR; García EM; de la Rosa RE
Int Urol Nephrol; 2023 Oct; 55(10):2629-2637. PubMed ID: 36952108
[TBL] [Abstract][Full Text] [Related]
18. Associations between Net Gastrointestinal Alkali Absorption, 24-Hour Urine Lithogenic Factors, and Kidney Stones.
Ferraro PM; Taylor EN; Asplin JR; Curhan GC
Clin J Am Soc Nephrol; 2023 Aug; 18(8):1068-1074. PubMed ID: 37256914
[TBL] [Abstract][Full Text] [Related]
19. Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease.
Gansevoort RT; van Gastel MDA; Chapman AB; Blais JD; Czerwiec FS; Higashihara E; Lee J; Ouyang J; Perrone RD; Stade K; Torres VE; Devuyst O;
Kidney Int; 2019 Jul; 96(1):159-169. PubMed ID: 30898339
[TBL] [Abstract][Full Text] [Related]
20. Short-Term Changes in Urinary Relative Supersaturation Predict Recurrence of Kidney Stones: A Tool to Guide Preventive Measures in Urolithiasis.
Ferraro PM; Ticinesi A; Meschi T; Rodgers A; Di Maio F; Fulignati P; Borghi L; Gambaro G
J Urol; 2018 Nov; 200(5):1082-1087. PubMed ID: 29940247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
